BRUKINSA Delivers Landmark 74% 6-Year PFS in Treatment-Naïve CLL
This data highlights BRUKINSA's sustained efficacy and durability in a challenging patient population.
BRUKINSA demonstrated 74% 6-year PFS in treatment-naïve CLL patients.
BeiGene announced landmark data from a Phase 3 study showing BRUKINSA achieved a 74% progression-free survival (PFS) rate at six years in patients with treatment-naïve chronic lymphocytic leukemia (CLL). This significant long-term efficacy data reinforces BRUKINSA's position as a leading treatment option for CLL.
This data highlights BRUKINSA's sustained efficacy and durability in a challenging patient population. For APAC, where CLL is a significant concern, these results reinforce the value of BRUKINSA as a long-term treatment option, potentially improving patient outcomes and quality of life across the region.
BRUKINSA is a key product for BeiGene in APAC. Demonstrating such strong long-term efficacy in treatment-naïve CLL patients is highly relevant for oncologists and patients in the region, supporting its continued adoption and clinical use.
Where this signal fits in the broader landscape.
BeiGene Announces Q4 and Full Year 2025 Financial Results
BeOne Medicines Announces Q4 and FY2025 Financial Results
BeiGene's PD-1 Inhibitor Tislelizumab Approved in Japan, Challenging Global Pharma Giants
BeOne Medicines to Announce Q4 and Full Year 2025 Financial Results
BeiGene's Sonrotoclax Receives First-in-World Approval in R/R MCL
https://www.beigene.com/press-releases/brukinsa-delivers-landmark-74-percent-6-year-progression-free-survival-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In